Cerevel Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders. The company was founded in 2018 as a spin-out from Pfizer and has since raised over $350 million in funding. Cerevel's pipeline includes treatments for Parkinson's disease, epilepsy, schizophrenia, and other CNS disorders.